135 related articles for article (PubMed ID: 19226702)
1. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats.
Revermann M; Barbosa-Sicard E; Dony E; Schermuly RT; Morisseau C; Geisslinger G; Fleming I; Hammock BD; Brandes RP
J Hypertens; 2009 Feb; 27(2):322-31. PubMed ID: 19226702
[TBL] [Abstract][Full Text] [Related]
2. Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice.
Revermann M; Schloss M; Barbosa-Sicard E; Mieth A; Liebner S; Morisseau C; Geisslinger G; Schermuly RT; Fleming I; Hammock BD; Brandes RP
Arterioscler Thromb Vasc Biol; 2010 May; 30(5):909-14. PubMed ID: 20224052
[TBL] [Abstract][Full Text] [Related]
3. Increases in plasma trans-EETs and blood pressure reduction in spontaneously hypertensive rats.
Jiang H; Quilley J; Doumad AB; Zhu AG; Falck JR; Hammock BD; Stier CT; Carroll MA
Am J Physiol Heart Circ Physiol; 2011 Jun; 300(6):H1990-6. PubMed ID: 21398593
[TBL] [Abstract][Full Text] [Related]
4. Soluble epoxide hydrolase gene deficiency or inhibition attenuates chronic active inflammatory bowel disease in IL-10(-/-) mice.
Zhang W; Yang AL; Liao J; Li H; Dong H; Chung YT; Bai H; Matkowskyj KA; Hammock BD; Yang GY
Dig Dis Sci; 2012 Oct; 57(10):2580-91. PubMed ID: 22588244
[TBL] [Abstract][Full Text] [Related]
5. Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension.
Kopkan L; Husková Z; Sporková A; Varcabová Š; Honetschlägerová Z; Hwang SH; Tsai HJ; Hammock BD; Imig JD; Kramer HJ; Bürgelová M; Vojtíšková A; Kujal P; Vernerová Z; Červenka L
Kidney Blood Press Res; 2012; 35(6):595-607. PubMed ID: 22948718
[TBL] [Abstract][Full Text] [Related]
6. Soluble epoxide hydrolase inhibition modulates vascular remodeling.
Simpkins AN; Rudic RD; Roy S; Tsai HJ; Hammock BD; Imig JD
Am J Physiol Heart Circ Physiol; 2010 Mar; 298(3):H795-806. PubMed ID: 20035028
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling.
Liu Y; Webb HK; Fukushima H; Micheli J; Markova S; Olson JL; Kroetz DL
J Pharmacol Exp Ther; 2012 Jun; 341(3):725-34. PubMed ID: 22414856
[TBL] [Abstract][Full Text] [Related]
8. EH3 (ABHD9): the first member of a new epoxide hydrolase family with high activity for fatty acid epoxides.
Decker M; Adamska M; Cronin A; Di Giallonardo F; Burgener J; Marowsky A; Falck JR; Morisseau C; Hammock BD; Gruzdev A; Zeldin DC; Arand M
J Lipid Res; 2012 Oct; 53(10):2038-2045. PubMed ID: 22798687
[TBL] [Abstract][Full Text] [Related]
9. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension.
Honetschlägerová Z; Husková Z; Vaňourková Z; Sporková A; Kramer HJ; Hwang SH; Tsai HJ; Hammock BD; Imig JD; Červenka L; Kopkan L
J Physiol; 2011 Jan; 589(Pt 1):207-19. PubMed ID: 21078594
[TBL] [Abstract][Full Text] [Related]
10. 11,12-Epoxyecosatrienoic acids mitigate endothelial dysfunction associated with estrogen loss and aging: Role of membrane depolarization.
Sun C; Simon SI; Foster GA; Radecke CE; Hwang HV; Zhang X; Hammock BD; Chiamvimonvat N; Knowlton AA
J Mol Cell Cardiol; 2016 May; 94():180-188. PubMed ID: 27079253
[TBL] [Abstract][Full Text] [Related]
11. The involvement of soluble epoxide hydrolase in the development of cardiovascular diseases through epoxyeicosatrienoic acids.
Jiang S; Han S; Wang DW
Front Pharmacol; 2024; 15():1358256. PubMed ID: 38628644
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease.
Jung O; Jansen F; Mieth A; Barbosa-Sicard E; Pliquett RU; Babelova A; Morisseau C; Hwang SH; Tsai C; Hammock BD; Schaefer L; Geisslinger G; Amann K; Brandes RP
PLoS One; 2010 Aug; 5(8):e11979. PubMed ID: 20694143
[TBL] [Abstract][Full Text] [Related]
13. Vascular pharmacology of epoxyeicosatrienoic acids.
Pfister SL; Gauthier KM; Campbell WB
Adv Pharmacol; 2010; 60():27-59. PubMed ID: 21081214
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation.
Davis BB; Thompson DA; Howard LL; Morisseau C; Hammock BD; Weiss RH
Proc Natl Acad Sci U S A; 2002 Feb; 99(4):2222-7. PubMed ID: 11842228
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor.
Lazaar AL; Yang L; Boardley RL; Goyal NS; Robertson J; Baldwin SJ; Newby DE; Wilkinson IB; Tal-Singer R; Mayer RJ; Cheriyan J
Br J Clin Pharmacol; 2016 May; 81(5):971-9. PubMed ID: 26620151
[TBL] [Abstract][Full Text] [Related]
16. Soluble epoxide hydrolase inhibition enhances production of specialized pro-resolving lipid mediator and promotes macrophage plasticity.
Abdalla HB; Alvarez C; Wu YC; Rojas P; Hammock BD; Maddipati KR; Trindade-da-Silva CA; Soares MQS; Clemente-Napimoga JT; Kantarci A; Napimoga MH; Van Dyke TE
Br J Pharmacol; 2023 Jun; 180(12):1597-1615. PubMed ID: 36508312
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of soluble epoxide hydrolase in proximal tubular cells mediated proteinuria-induced renal damage.
Wang Q; Pang W; Cui Z; Shi J; Liu Y; Liu B; Zhou Y; Guan Y; Hammock BD; Wang Y; Zhu Y
Am J Physiol Renal Physiol; 2013 Jan; 304(2):F168-76. PubMed ID: 23152298
[TBL] [Abstract][Full Text] [Related]
18. Soluble epoxide hydrolase regulates hematopoietic progenitor cell function via generation of fatty acid diols.
Frömel T; Jungblut B; Hu J; Trouvain C; Barbosa-Sicard E; Popp R; Liebner S; Dimmeler S; Hammock BD; Fleming I
Proc Natl Acad Sci U S A; 2012 Jun; 109(25):9995-10000. PubMed ID: 22665795
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotective response and senescence in aged sEH null female mice exposed to LPS.
Yousef A; Sosnowski DK; Fang L; Legaspi RJ; Korodimas J; Lee A; Magor KE; Seubert JM
Am J Physiol Heart Circ Physiol; 2024 Jun; 326(6):H1366-H1385. PubMed ID: 38578240
[TBL] [Abstract][Full Text] [Related]
20. The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells.
Mashayekhi M; Wanjalla CN; Warren CM; Simmons JD; Ghoshal K; Pilkinton M; Bailin SS; Gabriel CL; Pozzi A; Koethe JR; Brown NJ; Kalams SA; Luther JM
Prostaglandins Other Lipid Mediat; 2022 Feb; 158():106604. PubMed ID: 34922004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
